Status:
COMPLETED
Effect on Cognitive Function of a Treatment With Aripiprazole
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
Eligibility Criteria
Inclusion
- Diagnosis of Schizophrenia
- score of 2-6 in the CGI-S scale at basline
- ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment
Exclusion
- women of child bearing potential
- women pregnant or breast feeding
- patients with a score of 0,-1 or 7
- substance use
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00329810
Start Date
March 1 2005
End Date
March 1 2006
Last Update
November 8 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.